Faeth Therapeutics (FTH) Income towards Parent Company (2020 - 2026)

Faeth Therapeutics (FTH) has 7 years of Income towards Parent Company data on file, last reported at -$182.4 million in Q1 2026.

• Quarterly Income towards Parent Company fell 2378.78% year-over-year to -$182.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$200.1 million (down 446.53% YoY) and the FY2025 annual result came in at -$81.8 million, up 7.25% from the prior year.
• Income towards Parent Company eased to -$182.4 million in Q1 2026, from -$3.4 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$3.4 million in Q4 2025 to a low of -$182.4 million in Q1 2026.
• A 5-year average of -$20.2 million and a median of -$11.2 million in 2022 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2022 — Income towards Parent Company soared 57.83% — and 2026, when it tumbled 2378.78%.
• Tracing FTH's Income towards Parent Company over 5 years: stood at -$12.2 million in 2022, then soared by 44.54% to -$6.8 million in 2023, then increased by 12.09% to -$6.0 million in 2024, then surged by 42.22% to -$3.4 million in 2025, then tumbled by 5192.77% to -$182.4 million in 2026.
• The last three Income towards Parent Company figures came in at -$182.4 million (Q1 2026), -$3.4 million (Q4 2025), and -$6.7 million (Q3 2025), per Business Quant data.